Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.
Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch Center for Cancer Research, National Cancer Institute, Building 10, Bethesda, Maryland 20892, USA.
Austin G
AG
Duffy
Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch Center for Cancer Research, National Cancer Institute, Building 10, Bethesda, Maryland 20892, USA.
Tim F
TF
Greten
D000970:Antineoplastic Agents; D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D010671:Phenylurea Compounds; D011725:Pyridines
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib